Name: Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016
SKU: KLI4859780
Availability: InStock

Description

What Will the Pharma Industry Look Like in 5 Years?

There are an estimated 724 projects in development from the top 50 pharmaceutical companies. Together, they have the potential to add billions in value to the current pharmaceutical market in the next five years. What types of drugs are companies developing and what will be the impact of these products on the marketplace and key competitors? In this report, Kalorama Information has analyzed the late-stage R&D pipeline of the 50 top companies in pharmaceuticals — the companies that produce the lion’s share of industry revenues.

Coverage of the 50 Leading Companies This report takes a look at the pipeline of the following companies. The top companies include pharmaceutical companies that are considered to be the top 50 companies worldwide in terms of generated revenues, these include:

Abbott Laboratories
Actelion
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Biogen IDEC
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene Corp.
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly & Co.
Forest
Gilead Sciences
GlaxoSmithKline
Grifols SA
Hospira
Johnson & Johnson
Kyowa Kirin
Lundbeck
Menarini
Merck
Merck KGaA
Mitsubishi Tanabe Pharma
Mylan
Novartis
Novo Nordisk
Ono Pharmaceutical Co.
Otsuka Pharmaceutical
Pfizer
Purdue Pharma
Reckitt Benckiser
Roche
Sanofi
Santen Pharmaceuticals
Servier
Shionogi
Shire
Taisho Pharmacueitcal
Takeda
TEVA
UCB
Valeant Pharmaceuticals
Warner Chilcott
Watson

While the report looks at the entire pipeline to 2015, a key focus of the report is the increasing role of biopharmaceutical products. The growing interest in biotechnology development has transitioned the pharmaceutical industry to biopharmaceuticals in less than a decade. Companies such as Pfizer, Merck and Novartis have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts.

Pipeline Analysis, Key Trends, Market ForecastsThis Kalorama Information market research report captures these trends, extracting sales for all pharmaceutical and biopharmaceutical products (excluding prophylactic vaccines and OTC products) and providing estimates and forecasts of the world biopharma market.

As part of its coverage, the report provides the following:

Company Analysis
Pipeline Snapshot: Top 20 Companies
Market Trends and Value
Evaluating Changes in 2011 Market Value
The Traditional Pharmaceutical Market
Biotechnology Market Facts and Forecast

For the purpose of this study, Kalorama Information has extracted sales for human pharmaceutical and biopharmaceutical products; consumer pharmaceuticals and products; diagnostics; devices; chemicals; agriculture; and animal health. These are areas where many of these companies also compete with significant market shares.

The industry has struggled in recent years but many observers see biopharmaceutical as the key to continued success for market leaders. Biopharmaceuticals are defined as any substance produced by natural organisms or recombinant techniques consisting of proteins and other products derived from living organisms for the treatment or management of diseases or injuries. Biopharmaceuticals are created through fermentation, recombinant DNA technology, and other bioprocesses. The complex nature of biopharmaceuticals and the growing interest in development of these products has resulted in a flood of new issues affecting the already complicated healthcare market. There are a number of issues and trends which are experienced by the healthcare industry as a whole and others which are unique to biopharmaceuticals, their development and commercialization.

Issues and Trends discussed in this report include:

Biotechnology Drug Development
Orphan Drugs
Fast Track Drug Status
Other Accelerated Methods for Drug Approval
Pharmaceutical Regulatory Exclusivity
Biosimilar Development
Aging Populations
Mergers, Acquisitions, and Collaborations
Contributors to R&D Success
R&D Spending Trends
The Role of Contract Research Organizations
Sustainability in a Changing Pharmaceutical Industry

CHAPTER ONE: EXECUTIVE SUMMARY

IntroductionScope and Methodology
Potential Market Opportunity
Issues and Trends Affecting Market
Leading Companies

CHAPTER TWO: INTRODUCTION

Global Pharmaceutical MarketPharmaceutical Research & Development Overview
Expanded Options in Treating Diseases

CHAPTER THREE: ISSUES AND TRENDS

Biotechnology Drug DevelopmentOrphan Drugs
Fast Track Drug Status
Other Accelerated Methods for Drug Approval
Pharmaceutical Regulatory Exclusivity
Pediatric Extensions
Biopharmaceutical Industry—Biosimilar (Biogeneric) Development and Exclusivity Legislation
Aging Population
Mergers, Acquisitions, and Collaborations
Contributors To R&D Success
R&D Spending
The Role of Contract Research Organization
Sustainability in a Changing Pharmaceutical Industry

CHAPTER FOUR: WORLDWIDE PHARMACEUTICAL INDUSTRY LEADERS

IntroductionPfizer, Inc.
- Overview
- Financial Performance and Investments
- Late Stage Pipeline
Merck & Co., Inc.
- Overview
- Financial Performance and Investments
- Late Stage Pipeline
Novartis
- Overview
- Financial Performance and Investments
- Late Stage Pipeline
Sanofi
- Overview
- Financial Performance and Investments
- Late Stage Pipeline
Roche Ltd.
- Overview
- Financial Performance and Investments
- Late Stage Pipeline
GlaxoSmithKline plc
- Overview
- Financial Performance and Investments
- Late Stage Pipeline
AstraZeneca plc
- Overview
- Financial Performance and Investments
- Late Stage Pipeline
Johnson & Johnson
- Overview
- Financial Performance and Investments
- Late Stage Pipeline
Eli Lilly & Company
- Overview
- Financial Performance and Investments
- Late Stage Pipeline
Abbott Laboratories
- Overview
- Financial Performance and Investments
- Late Stage Pipeline
Bristol-Myers Squibb Company
- Overview
- Financial Performance and Investments
- Late Stage Pipeline
Takeda Pharmaceutical Co., Ltd.
- Overview
- Financial Performance and Investments
- Late Stage Pipeline
TEVA Pharmaceutical Industries, Ltd.
- Overview
- Financial Performance and Investments
- Late Stage Pipeline
Amgen, Inc.
- Overview
- Financial Performance and Investments
- Late Stage Pipeline
Boehringer Ingelheim GmbH
- Overview
- Financial Performance and Investments
- Late Stage Pipeline
Bayer AG
- Overview
- Financial Performance and Investments
- Late Stage Pipeline
Novo Nordis
- Overview
- Financial Performance and Investments
- Late Stage Pipeline
Astellas
- Overview
- Financial Performance and Investments
- Late Stage Pipeline
Daiichi Sankyo
- Overview
- Financial Performance and Investmen
- Late Stage Pipeline
Otsuka
- Overview
- Financial Performance and Investments
- Late Stage Pipeline

CHAPTER FIVE: COMPANIES OF INTEREST

IntroductionMerck KGaA
- Late Stage Pipeline
Gilead Sciences
- Late Stage Pipeline
Eisai
- Late Stage Pipeline
Mylan
- Pipeline
Baxter International
- Pipeline
Servier, Les Laboratories
- Pipeline
Celgene Corporation
- Late Stage Pipeline
Mitsubishi Tanabe
- Late Stage Pipeline
Allergan
- Late Stage Pipeline
Forest Laboratories
- Late Stage Pipeline
CSL Limited
- Late Stage Pipeline
UCB SA
- Late Stage Pipeline
Dainippon Sumitomo Pharma, Co., Ltd.
- Late Stage Pipeline
Shire
- Late Stage Pipeline
Biogen Idec
- Late Stage Pipeline
Watson
- Pipeline
Hospira
- Late Stage Pipeline
Lundbeck A/S
- Late Stage Pipeline
Kyowa Kirin
- Late Stage Pipeline
Warner Chilcott plc
- Late Stage Pipeline
Menarini Group
- Late Stage Pipeline
Valeant Pharmaceuticals
- Late Stage Pipeline
Purdue Pharma
- Late Stage Pipeline
Grifols SA
- Late Stage Pipeline
Shionogi & Co., Ltd.
- Late Stage Pipeline
Actelion
- Late Stage Pipeline
Ono Pharmaceutical Co.
- Late Stage Pipeline
Santen Pharmaceutical Co.
- Late Stage Pipeline
Reckitt Benckiser
- Late Stage Pipeline
Taisho Pharmaceutical Co.
- Late Stage Pipeline

CHAPTER SIX: MARKET FORECAST

OverviewCompany Analysis
Pipeline Snapshot: Top 20 Companies
Market Trends and Value
Evaluating Changes in 2011 Market Value
Market Forecast
The Traditional Biotechnology Market
Biotechnology Market Facts and Forecast

APPENDIX: LIST OF COMPANIES

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

Table 1-1: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2016—based on late stage development projects evaluatedFigure 1-1: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2016—Potential Impact from Late-Stage Development

CHAPTER TWO: INTRODUCTION

Table 2-1: Total Healthcare Expenditures as a Percent of GDP by Country 1990, 2000 and 2009Figure 2-1: Total Healthcare Expenditures as a Percent of GDP by Country 1990, 2000, and 2009
Table 2-2: Phases of Clinical Drug Development
Table 2-3: Components of a Clinical Trial
Figure 2-2: Biotechnology Approvals by Year Range (FDA)

CHAPTER THREE: ISSUES AND TRENDS

Table 3-1: International Population Trend Age 65+Table 3-2: United States Population Trend Age 65+
Table 3-3: Recent Pharmaceutical Business Mergers and Acquisitions
Table 3-4: Pharmaceutical/Biopharmaceutical R&D Statistics
Table 3-5: Total Industry R&D Spending 2004-2010

CHAPTER FOUR: WORLDWIDE PHARMACEUTICAL INDUSTRY LEADERS

Table 4-1: Top Biopharmaceutical Companies, 1-20 by 2011 SalesTable 4-2: Pfizer’s Total Company Revenue and R&D Spending 2007-2011
Figure 4-1: Pfizer’s Total Company Revenue and R&D Spending 2007-2011
Table 4-3: Pfizer’s Late Stage Product Pipeline
Figure 4-2: Pfizer’s Late Stage Product Pipeline by Therapeutic Area
Table 4-4: Merck’s* Total Company Revenue and R&D Spending 2007-2011
Table 4-5: Merck’s Late Stage Product Pipeline
Table 4-5 (continued): Merck’s Late Stage Product Pipeline
Figure 4-4: Merck’s Late Stage Product Pipeline by Therapeutic Area
Table 4-6: Novartis’ Total Company Revenue and R&D Spending 2007-2011
Table 4-7: Novartis’ Late Stage Product Pipeline
Figure 4-7: Novartis’ Late Stage Product Pipeline by Therapeutic Area
Table 4-8: Sanofi’s Total Company Revenue and R&D Spending 2007-2011
Table 4-9: Sanofi-Aventis’ Late Stage Product Pipeline
Figure 4-8: Sanofi Aventis’ Late Stage Product Pipeline by Therapeutic Area
Table 4-10: Roche’s Total Company Revenue and R&D Spending 2007-2011
Table 4-11: Roche’s Late Stage Product Pipeline
Figure 4-10: Roche’s Late Stage Product Pipeline by Therapeutic Area
Table 4-12: GlaxoSmithKline’s Total Company Revenue and R&D Spending 2007-2011
Table 4-13: GlaxoSmithKline’s Late Stage Product Pipeline
Figure 4-12: GlaxoSmithKline’s Late Stage Product Pipeline by Therapeutic Area
Table 4-14: AstraZeneca’s Total Company Revenue and R&D Spending 2007-2011
Table 4-15: AstraZeneca’s Late Stage Product Pipeline
Figure 4-14: AstraZeneca’ Late Stage Product Pipeline by Therapeutic Area
Table 4-16: Johnson & Johnson’s Total Company Revenue and R&D Spending 2007-2011
Table 4-17: Johnson & Johnson’s Late Stage Product Pipeline
Table 4-18: Eli Lilly’s Total Company Revenue and R&D Spending 2007-2011
Table 4-19: Eli Lilly’s Late Stage Product Pipeline
Figure 4-18: Eli Lilly & Co.’s Late Stage Product Pipeline by Therapeutic Area
Table 4-20: Abbott’s Total Company Revenue and R&D Spending 2007-2011
Table 4-21: Abbott’s Late Stage Product Pipeline
Figure 4-20: Abbott’s Late Stage Product Pipeline by Therapeutic Area
Table 4-22: Bristol-Myers Squibb’s Total Company Revenue and R&D Spending 2007-2011
Table 4-23: Bristol-Myers Squibb’s Late Stage Product Pipeline
Table 4-23: Bristol-Myers Squibb’s Late Stage Product Pipeline
Figure 4-22: Bristol-Myers’ Late Stage Product Pipeline by Therapeutic Area
Table 4-24: Takeda’s Total Company Revenue* and R&D Spending 2007-2011
Table 4-25: Takeda Pharmaceutical’s Late Stage Product Pipeline
Figure 4-24: Takeda Pharmaceutical’s Late Stage Product Pipeline by Therapeutic Area
Table 4-26: TEVA’s Total Company Revenue and R&D Spending 2007-2011
Table 4-27: TEVA’s Late Stage Product Pipeline
Figure 4-26: TEVA’s Late Stage Product Pipeline by Therapeutic Area
Table 4-28: Amgen’s Total Company Revenue and R&D Spending 2007-2011
Table 4-29: Amgen’s Late Stage Product Pipeline
Figure 4-28: Amgen’s Late Stage Product Pipeline by Therapeutic Area
Table 4-30: Boehringer Ingelheim’s Total Company Revenue and R&D Spending 2007-2011
Table 4-31: Boehringer Ingelheim’s Late Stage Product Pipeline
Figure 4-30: Boehringer Ingelheim’s Late Stage Product Pipeline by Therapeutic Area
Table 4-32: Bayer’s Total Company Revenue and R&D Spending 2007-2011
Table 4-33: Bayer’s Late Stage Product Pipeline
Figure 4-32: Bayers’ Late Stage Product Pipeline by Therapeutic Area
Table 4-34: Novo Nordisk’s Total Company Revenue and R&D Spending 2007-2011
Table 4-35: Novo Nordisk’s Late Stage Product Pipeline
Figure 4-34: Novo Nordisk’s Late Stage Product Pipeline by Therapeutic Area
Table 4-36: Astellas’ Total Company Revenue and R&D Spending 2007-2011
Table 4-37: Astellas’ Late Stage Product Pipeline
Figure 4-36: Astellas’ Late Stage Product Pipeline by Therapeutic Area
Table 4-38: Daiichi Sankyo’s Total Company Revenue and R&D Spending 2007-2011
Table 4-39: Daiichi Sankyo’s Late Stage Product Pipeline
Figure 4-38: Daiichi Sankyo’s Late Stage Product Pipeline by Therapeutic Area
Table 4-40: Otsuka Holding’s Total Company Revenue and R&D Spending 2007-2011
Table 4-41: Otsuka Pharmaceutical’s Late Stage Product Pipeline
Figure 4-40: Otsuka Pharmaceutical’s Late Stage Product Pipeline by Therapeutic Area

CHAPTER FIVE: COMPANIES OF INTEREST

Table 5-1: Top Biopharmaceutical Companies, 21-50 by 2011 SalesTable 5-2: Merck KGaA’s Late Stage Product Pipeline
Table 5-3: Gilead Sciences’ Late Stage Product Pipeline
Table 5-4: Eisai’s Late Stage Product Pipeline
Table 5-5: Celgene’s Late Stage Product Pipeline
Table 5-6: Mitsubishi Tanabe’s Late Stage Product Pipeline
Table 5-7: Allergan’s Late Stage Product Pipeline
Table 5-8: Forest Laboratories’ Late Stage Product Pipeline
Table 5-9: UCB Pharma’s Late Stage Product Pipeline
Table 5-10: Dainippon Sumitomo’s Late Stage Product Pipeline
Table 5-11: Shire’s Late Stage Product Pipeline
Table 5-12: Biogen Idec’s Late Stage Product Pipeline
Table 5-13: Hospira’s Late Stage Product Pipeline
Table 5-14: Lundbeck’s Late Stage Product Pipeline
Table 5-15: Kyowa Kirin’s Late Stage Product Pipeline
Table 5-16: Menarini’s Late Stage Product Pipeline
Table 5-17: Valeant’s Late Stage Product Pipeline
Table 5-18: Shionogi’s Late Stage Product Pipeline
Table 5-19: Actelion’s Late Stage Product Pipeline
Table 5-20: Ono Pharmaceutical’s Late Stage Product Pipeline
Table 5-21: Santen’s Late Stage Product Pipeline
Table 5-22: Taisho’s Late Stage Product Pipeline

CHAPTER SIX: MARKET FORECAST

Table 6-1: Top Biopharmaceutical Companies, 1-50 by 2011 SalesTable 6-1 (Continued): Top Pharmaceutical/Biopharmaceutical Companies, 1-50 by 2011 Sales
Table 6-2: Company Pipelines by Total Late Stage Development Projects
(Top 20 Companies by Revenues)
Figure 6-1: Company Pipelines by Total Late Stage Development Projects (Top 20 Companies by Revenues)
Table 6-3: Global Pharmaceutical Market Value by Therapeutic Segment, 2005-2010
Figure 6-2: Global Pharmaceutical Market Value by Therapeutic Segment, 2005-2010
Table 6-4: Global Pharmaceutical Market Value by Therapeutic Segment, 2010 vs. 2011
Figure 6-3: Global Pharmaceutical Market Value by Therapeutic Segment, 2010 vs. 2011
Table 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2016—based on late stage development projects evaluated
Figure 6-4: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2016—based on late stage development projects evaluated
Figure 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2016—Potential Impact from Late-Stage Development
Figure 6-6: Global Pharmaceutical Market Forecast by, 2016—Potential Impact from Late-Stage Development
Table 6-6: Top 5 Biotechnology Companies*, 2011 Sales
Table 6-7: Top 10 Biotechnology and Pharmaceutical Products, by 2011 Revenues
Figure 6-7: Top 10 Biotechnology and Pharmaceutical Products, by 2011 Revnues

Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016

Description

Table of Contents

Contact Us

Pay Invoice

Follow Us!

Latest Blogs

Sitemap

Your Data and Privacy

About Us